DNA
Ginkgo Bioworks Holdings, Inc.
NYSE · Healthcare · Biotechnology · US
$11.65
+8.27%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$10.88
From 52W high−22.23%
Volume2.68M
Market cap$784.51M
P/E (TTM)—
P/S (TTM)7.0x
Div yield—
Key dataNov 4, 2026
Open
$10.88
From 52W high
−22.23%
Volume
2.68M
Market cap
$784.51M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
P/E (TTM)
—
RSI (14)
52.0
MomentumView details →
1D Return
+8.27%
YTD Return
+34.54%
SummaryUpdated Jun 1, 2026
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a biotechnology platform company founded in 2008 and headquartered in Boston, Massachusetts. The company went public in April 2021 through a SPAC merger. Ginkgo operates as a "platform for cell programming," essentially functioning as a biotechnology foundry that engineers microorganisms to produce various products for customers across multiple industries. The company has evolved from a pure-play cell engineering service provider to a diversified biotechnology platform offering cell programming services, biosecurity solutions, and laboratory automation tools.
Similar companies
Latest newsMore news →
Ginkgo Bioworks Holdings, Inc. shares fell 4.35% to close at $12.74.6d agoGinkgo Bioworks Holdings, Inc. shares fell 2.09% to close at $9.86.15d agoSwitch Bioworks entered a strategic collaboration with Bayer CropScience AG to combine Switch’s microbial strains with Bayer’s crop hybrids and advance switchable biofertilizer technology.22d ago